Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
INSY's Cash-to-Debt is ranked higher than
96% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. INSY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INSY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.79
INSY's Equity-to-Asset is ranked higher than
68% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INSY: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
INSY' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.45  Med: 0.79 Max: 0.98
Current: 0.79
-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
95% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s Interest Coverage Range Over the Past 10 Years
Min: 34.27  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 5.44
Beneish M-Score: -3.25
WACC vs ROIC
15.35%
-15.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -12.55
INSY's Operating Margin % is ranked higher than
65% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. INSY: -12.55 )
Ranked among companies with meaningful Operating Margin % only.
INSY' s Operating Margin % Range Over the Past 10 Years
Min: -324863.64  Med: -74.22 Max: 32.79
Current: -12.55
-324863.64
32.79
Net Margin % -8.07
INSY's Net Margin % is ranked higher than
67% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. INSY: -8.07 )
Ranked among companies with meaningful Net Margin % only.
INSY' s Net Margin % Range Over the Past 10 Years
Min: -301890.91  Med: -77.2 Max: 40.67
Current: -8.07
-301890.91
40.67
ROE % -5.79
INSY's ROE % is ranked higher than
72% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. INSY: -5.79 )
Ranked among companies with meaningful ROE % only.
INSY' s ROE % Range Over the Past 10 Years
Min: -130.7  Med: -46.69 Max: 545.67
Current: -5.79
-130.7
545.67
ROA % -4.48
INSY's ROA % is ranked higher than
73% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. INSY: -4.48 )
Ranked among companies with meaningful ROA % only.
INSY' s ROA % Range Over the Past 10 Years
Min: -118.94  Med: -54.65 Max: 67.69
Current: -4.48
-118.94
67.69
ROC (Joel Greenblatt) % -53.60
INSY's ROC (Joel Greenblatt) % is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. INSY: -53.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2087.93  Med: -971.57 Max: 204.03
Current: -53.6
-2087.93
204.03
3-Year Revenue Growth Rate 23.70
INSY's 3-Year Revenue Growth Rate is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. INSY: 23.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -21.5 Max: 500
Current: 23.7
0
500
3-Year EBITDA Growth Rate -32.60
INSY's 3-Year EBITDA Growth Rate is ranked lower than
85% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. INSY: -32.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INSY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 7.35 Max: 170.4
Current: -32.6
-72.2
170.4
3-Year EPS without NRI Growth Rate -47.70
INSY's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. INSY: -47.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INSY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -70.3  Med: -0.4 Max: 331.8
Current: -47.7
-70.3
331.8
GuruFocus has detected 2 Warning Signs with Insys Therapeutics Inc INSY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INSY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

INSY Guru Trades in Q3 2016

Paul Tudor Jones 13,398 sh (New)
Steven Cohen 367,143 sh (New)
Lee Ainslie 203,860 sh (New)
Jim Simons 264,500 sh (+15.20%)
Joel Greenblatt 327,060 sh (-65.35%)
» More
Q4 2016

INSY Guru Trades in Q4 2016

Arnold Schneider 44,973 sh (New)
Paul Tudor Jones 42,405 sh (+216.50%)
Lee Ainslie 274,211 sh (+34.51%)
Steven Cohen 348,627 sh (-5.04%)
Jim Simons 241,500 sh (-8.70%)
Joel Greenblatt 207,055 sh (-36.69%)
» More
Q1 2017

INSY Guru Trades in Q1 2017

Arnold Schneider 59,973 sh (+33.35%)
Steven Cohen 435,000 sh (+24.78%)
Paul Tudor Jones 49,589 sh (+16.94%)
Lee Ainslie Sold Out
Joel Greenblatt 198,574 sh (-4.10%)
Jim Simons 45,200 sh (-81.28%)
» More
Q2 2017

INSY Guru Trades in Q2 2017

Murray Stahl 35,236 sh (New)
Arnold Schneider 119,973 sh (+100.05%)
Steven Cohen Sold Out
Jim Simons 35,000 sh (-22.57%)
Joel Greenblatt 70,484 sh (-64.50%)
Paul Tudor Jones 11,767 sh (-76.27%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Arnold Schneider 2017-06-30 Add 100.05%0.15%$10.03 - $14.7 $ 7.54-36%119,973
Joel Greenblatt 2017-06-30 Reduce -64.50%0.02%$10.03 - $14.7 $ 7.54-36%70,484
Joel Greenblatt 2017-03-31 Reduce -4.10%$9.5 - $13.48 $ 7.54-29%198,574
Arnold Schneider 2017-03-31 Add 33.35%0.03%$9.5 - $13.48 $ 7.54-29%59,973
Joel Greenblatt 2016-12-31 Reduce -36.69%0.02%$9.07 - $14.53 $ 7.54-33%207,055
Arnold Schneider 2016-12-31 New Buy0.07%$9.07 - $14.53 $ 7.54-33%44,973
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:SZSE:002286, NAS:WVE, NAS:AKAO, NAS:AMAG, NAS:CTMX, SZSE:300181, NAS:MGNX, NAS:DOVA, TSE:4592, SZSE:300049, XKRX:096530, ASX:SRX, NAS:CHRS, NAS:ABEO, NAS:MCRB, NAS:CRSP, HKSE:01681, NAS:ACIU, XKRX:078160, XPAR:IPH » details
Traded in other countries:NPR1.Germany,
Headquarter Location:USA
Insys Therapeutics Inc develops and commercializes drugs delivery systems targeting the oncology space. The company manufactures cannabinoid formulation, and sublingual spray drug delivery technology for the US and Europe markets.

Insys Therapeutics is a biotechnology company that develops and commercializes innovative drugs and novel drug delivery systems. The company maintains cannabinoid formulation and manufacturing, as well as sublingual spray drug delivery technology, to develop a portfolio of differentiated, wholly owned product candidates. Insys continues to specifically target oncology healthcare providers and practices. The company's sublingual spray delivery system is sourced, manufactured, and assembled by multiple third parties across the United States and Europe.

Ratios

vs
industry
vs
history
PB Ratio 2.03
INSY's PB Ratio is ranked higher than
72% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INSY: 2.03 )
Ranked among companies with meaningful PB Ratio only.
INSY' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 1.78 Max: 19.87
Current: 2.03
0.06
19.87
PS Ratio 2.88
INSY's PS Ratio is ranked higher than
79% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. INSY: 2.88 )
Ranked among companies with meaningful PS Ratio only.
INSY' s PS Ratio Range Over the Past 10 Years
Min: 1.74  Med: 11.1 Max: 29890
Current: 2.88
1.74
29890
Price-to-Free-Cash-Flow 74.70
INSY's Price-to-Free-Cash-Flow is ranked lower than
84% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. INSY: 74.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INSY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.31  Med: 46.18 Max: 167.27
Current: 74.7
11.31
167.27
Price-to-Operating-Cash-Flow 24.40
INSY's Price-to-Operating-Cash-Flow is ranked lower than
55% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. INSY: 24.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INSY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10  Med: 30.05 Max: 1288.75
Current: 24.4
10
1288.75
EV-to-EBIT -16.94
INSY's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. INSY: -16.94 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.9  Med: 0.7 Max: 94.8
Current: -16.94
-130.9
94.8
EV-to-EBITDA -23.79
INSY's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. INSY: -23.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1165.5  Med: 0.7 Max: 72.1
Current: -23.79
-1165.5
72.1
EV-to-Revenue 2.14
INSY's EV-to-Revenue is ranked higher than
85% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. INSY: 2.14 )
Ranked among companies with meaningful EV-to-Revenue only.
INSY' s EV-to-Revenue Range Over the Past 10 Years
Min: -24444.8  Med: 3.2 Max: 15687.1
Current: 2.14
-24444.8
15687.1
Current Ratio 3.13
INSY's Current Ratio is ranked lower than
60% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INSY: 3.13 )
Ranked among companies with meaningful Current Ratio only.
INSY' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 5.67 Max: 318.82
Current: 3.13
0.14
318.82
Quick Ratio 2.81
INSY's Quick Ratio is ranked lower than
60% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. INSY: 2.81 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.67 Max: 318.82
Current: 2.81
0.06
318.82
Days Inventory 380.86
INSY's Days Inventory is ranked lower than
89% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. INSY: 380.86 )
Ranked among companies with meaningful Days Inventory only.
INSY' s Days Inventory Range Over the Past 10 Years
Min: 169.77  Med: 427.32 Max: 1095
Current: 380.86
169.77
1095
Days Sales Outstanding 45.77
INSY's Days Sales Outstanding is ranked higher than
66% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. INSY: 45.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67  Med: 44.22 Max: 72.85
Current: 45.77
0.67
72.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
INSY's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. INSY: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -269.6  Med: -14.1 Max: 49.5
Current: -2.7
-269.6
49.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.69
INSY's Price-to-Net-Cash is ranked lower than
57% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. INSY: 7.69 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 8.91 Max: 69.25
Current: 7.69
1
69.25
Price-to-Net-Current-Asset-Value 4.31
INSY's Price-to-Net-Current-Asset-Value is ranked higher than
63% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. INSY: 4.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.98  Med: 6.75 Max: 91.93
Current: 4.31
0.98
91.93
Price-to-Tangible-Book 2.04
INSY's Price-to-Tangible-Book is ranked higher than
78% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. INSY: 2.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 5.21 Max: 84.45
Current: 2.04
0.55
84.45
Price-to-Intrinsic-Value-Projected-FCF 1.30
INSY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. INSY: 1.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INSY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.26  Med: 5.75 Max: 41.26
Current: 1.3
1.26
41.26
Price-to-Median-PS-Value 0.26
INSY's Price-to-Median-PS-Value is ranked higher than
89% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. INSY: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INSY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 4.67 Max: 3178.83
Current: 0.26
0.17
3178.83
Earnings Yield (Greenblatt) % -5.92
INSY's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. INSY: -5.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3345.9  Med: 4.9 Max: 2305
Current: -5.92
-3345.9
2305

More Statistics

Revenue (TTM) (Mil) $191.17
EPS (TTM) $ -0.21
Beta2.17
Short Percentage of Float46.46%
52-Week Range $7.27 - 15.06
Shares Outstanding (Mil)72.70

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 154 200 252 215
EPS ($) -0.43 -0.25 0.19 -0.21
EPS without NRI ($) -0.43 -0.25 0.19 -0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}